IgE antibody specific to house dust mite allergen (IgE (house dust mite-specific) or HDM-specific IgE)

House dust mite antigen-specific IgE refers to immunoglobulin E antibodies generated by B cells in response to sensitization with house dust mite proteins (commonly Dermatophagoides pteronyssinus and D. farinae). These IgE antibodies bind to high-affinity receptors (FcεRI) on mast cells and basophils, priming them for activation. Re-exposure to HDM allergens crosslinks the IgE and triggers degranulation, releasing histamine and inflammatory mediators that drive symptoms of allergic rhinitis, asthma, and atopic dermatitis. Group 1 and 2 HDM allergens are most commonly implicated in IgE-mediated disease[1][3][6]. Measurements of HDM-specific IgE in serum are widely used for diagnosis and monitoring in allergy clinics[6]. In contrast to a drug target, HDM-specific IgE is not itself a molecule to inhibit but marks the pathogenic mechanism of disease and guides immunotherapy approaches. Key clarification: In allergology and immunology, true molecular targets for drugs or diagnostics are the HDM proteins (allergens) like Der p 1, Der p 2, Der p 5, Der p 21, and Der p 23, not the IgE antibody itself except in the context of anti-IgE therapies like omalizumab[1][2][3][5][6]. The antibody is a disease biomarker, not a classical therapeutic target.

Other names

HDM-specific IgEIgE antibody to house dust miteanti-Dermatophagoides IgEmite-specific IgE

Omalizumab binds to free IgE, preventing its interaction with FcεRI on effector cells, thus reducing allergic inflammation